Ivermectin in Cancer: Mechanistic Rationale, Safety Profile, and Comparison With Chemotherapy

Introduction

Ivermectin is a long-established antiparasitic drug that has been used globally for decades. Beyond its approved role in treating parasitic infections, ivermectin has gained increasing attention in the fields of longevity medicine, repurposed-drug oncology, and integrative cancer research.

This interest is not based on a single mechanism or isolated claim, but on a convergence of factors: a long human safety record, multi-pathway biological activity relevant to cancer biology, immune-modulating effects, and experimental evidence suggesting selective pressure on malignant cells. As a result, ivermectin is now widely discussed and used off-label both for cancer treatment and cancer prevention, particularly in strategies focused on early intervention, recurrence reduction, and immune surveillance.

This article examines how ivermectin is used off-label, why it is proposed for both treatment and prevention, the mechanisms underlying these uses, how it differs from traditional chemotherapy, and the safety considerations relevant to long-term or preventive contexts.


Repurposed Drugs in Longevity and Cancer Prevention
 

Modern cancer biology increasingly recognizes that malignancy develops over years or decades through accumulated genetic damage, metabolic dysfunction, chronic inflammation, and immune escape.

Longevity-oriented medicine, therefore, emphasizes on:

• elimination of pre-malignant cells

• maintenance of immune surveillance

• metabolic stress on unstable or damaged cells

• prevention of recurrence after remission

Repurposed drugs are particularly attractive in this framework because they often:

• act across multiple signaling pathways simultaneously

• impose low-grade stress that malignant cells tolerate poorly

• interact with immune signaling rather than suppress immunity

• allow intermittent or cyclic use rather than continuous cytotoxic exposure
   

Ivermectin fits squarely within this paradigm, which explains its widespread discussion alongside other repurposed antiparasitic agents in preventive oncology contexts.

Mechanisms by Which Ivermectin Targets Malignant Cells

1. Immunogenic Cancer Cell Death

One of the most significant findings in ivermectin research is its ability to induce immunogenic cell death (ICD) in cancer models. Unlike silent apoptosis, ICD triggers inflammatory signaling that actively engages the immune system.

Ivermectin has been shown to modulate ATP-gated purinergic signaling through P2X4 and P2X7 receptors and pannexin-1 channels, leading to extracellular ATP release and inflammatory tumor cell death (Draganov et al., 2015). This process enhances antigen presentation and immune recognition of dying cancer cells.

Further work demonstrated that ivermectin induces ICD in breast cancer models and increases cytotoxic T-cell infiltration, converting immunologically “cold” tumors into “hot” tumors responsive to immune attack (Draganov et al., 2021).

Relevance to prevention:

If early malignant or pre-malignant cells undergo immunogenic elimination, immune surveillance may improve, reducing the likelihood of malignant progression or recurrence.

2. Enhancement of Immune Surveillance

Cancer progression requires immune evasion. Experimental data indicate that ivermectin can reshape the tumor microenvironment by:

• increasing effector T-cell infiltration

• reducing immune exclusion

• amplifying immune-mediated tumor clearance

Relevance to prevention

These effects are particularly relevant in early disease stages, where immune recognition may determine whether abnormal cell clones expand or are eliminated.

3. Disruption of Oncogenic Signaling Pathways

Ivermectin has been reported to influence several signaling pathways frequently dysregulated in cancer, including:

• Wnt/β-catenin

• PI3K/Akt/mTOR

• STAT3

• PAK1-associated signaling
   

These pathways regulate proliferation, survival, inflammation, stemness, and immune evasion. Reviews of ivermectin’s anticancer activity consistently describe multi-pathway interference rather than a single-target mechanism (Tang et al., 2020; Robalino et al., 2025).

Relevance to prevention:

Oncogenic signaling abnormalities often precede detectable tumors by many years. Dampening these pathways may slow or interrupt malignant evolution at early stages.

4. Selective Metabolic and Mitochondrial Stress

Malignant cells operate close to metabolic failure due to mitochondrial dysfunction, elevated oxidative stress, and altered energy metabolism. Ivermectin has been shown in experimental systems to:

• increase reactive oxygen species

• disrupt mitochondrial homeostasis

• induce programmed cell death
   

Normal cells, with intact stress-response capacity, appear more resilient to these effects.

Relevance to prevention:

Selective metabolic stress may preferentially eliminate damaged or genomically unstable cells before malignant expansion occurs.

5. Effects on Cancer Stem-Like Cells

Cancer stem-like cells are implicated in recurrence, metastasis, and resistance to therapy. Some experimental data suggest ivermectin affects stemness-associated pathways and survival mechanisms, potentially reducing the persistence of malignant cell reservoirs (Tang et al., 2020).

Relevance to prevention:

Targeting stem-like cells is central to long-term cancer control and recurrence prevention.


Comparison With Traditional Chemotherapy


Traditional Chemotherapy

Conventional chemotherapy is designed to kill rapidly dividing cells by damaging DNA or disrupting mitosis. While effective, this approach:

• harms healthy tissues

• suppresses immune function

• carries cumulative systemic toxicity
   

Chemotherapy is primarily reactive, deployed after cancer is established.

Ivermectin’s Conceptual Role

Ivermectin is not a classical cytotoxic agent. Its proposed role differs fundamentally:

• immune-modulating rather than immune-suppressive

• multi-pathway rather than single-target

• potentially compatible with intermittent use

Safety Profile and Long-Term Considerations
 

General Safety

Ivermectin has been administered to hundreds of millions of individuals worldwide. At standard antiparasitic doses, it is generally well tolerated (FDA, 2009).

However, off-label use introduces additional considerations:

• longer duration of use

• repeated cycles

• combination with other agents

• use in medically complex populations

Blood–Brain Barrier and Transporter Effects

Ivermectin is normally excluded from the central nervous system by P-glycoprotein transporters at the blood–brain barrier. Impaired transporter function or drug interactions can increase CNS exposure (Edwards, 2003).

Drug–Drug Interactions

Ivermectin is metabolized via CYP3A4 and interacts with P-glycoprotein. Caution is warranted when combined with:

• anticoagulants

• anti-seizure medications

• certain antibiotics and antifungals

A published case report describes warfarin toxicity associated with ivermectin use, highlighting the importance of interaction screening (Gilbert and Slechta, 2018).

Translational and Clinical Signals

Immunogenic Cell Death Research

Experimental models consistently demonstrate ivermectin-induced immunogenic tumor cell death and immune activation (Draganov et al., 2015; 2021).

Combination Therapy Trials

Clinical trials investigating ivermectin in combination with immunotherapy reflect serious translational interest and ongoing evaluation of its role in oncology (ClinicalTrials.gov NCT05318469).

Real-World Observational Use

Outside formal trials, ivermectin is widely incorporated into repurposed-drug and longevity-focused oncology strategies due to:

• low relative toxicity

• immune-supportive mechanisms

• compatibility with preventive frameworks
  
   

A Forward-Looking Role in Preventive and Longevity-Focused Oncology


Why Ivermectin Matters Going Forward

Ivermectin represents a shift in how cancer is approached—not as an isolated event requiring extreme intervention, but as a biological process that can be disrupted early and repeatedly.

Its appeal in longevity-focused oncology lies in several defining characteristics:

• it targets immune evasion, not just tumor growth

• it applies selective pressure rather than indiscriminate toxicity

• it interferes with early oncogenic signaling, not only late-stage disease

• it aligns with intermittent, long-term preventive strategies

Rather than functioning as a blunt cytotoxic weapon, ivermectin operates as a systems-level disruptor of malignant viability—making the internal environment less permissive to cancer development and persistence. As clinical research continues and combination strategies evolve, ivermectin is increasingly positioned not as an alternative to oncology, but as a complement to modern cancer prevention and immune-centered treatment paradigms. For longevity medicine, its significance lies in the possibility of maintaining immune dominance over malignancy, rather than reacting after that dominance has already been lost.

References

Draganov, D., Gopalakrishna-Pillai, S., Chen, Y-R. et al. (2015) ‘Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death’, Scientific Reports, 5, 16222.

Draganov, D. et al. (2021) ‘Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for breast cancer treatment’, npj Breast Cancer, 7, 22.

Edwards, G. (2003) ‘Ivermectin: does P-glycoprotein play a role in neurotoxicity?’, FASEB Journal, 17(8), pp. 123–125.

Food and Drug Administration (FDA) (2009) STROMECTOL (ivermectin) Prescribing Information. Silver Spring, MD: FDA.

Gilbert, B.W. and Slechta, J. (2018) ‘A case of ivermectin-induced warfarin toxicity’, Hospital Pharmacy, 53(2), pp. 123–126.

Robalino, K.N. et al. (2025) ‘Ivermectin as an alternative anticancer agent: mechanisms and translational challenges’, Pharmaceuticals, 18(2), 112.

Tang, M. et al. (2020) ‘Ivermectin, a potential anticancer drug derived from an antiparasitic agent’, Biochemical Pharmacology, 175, 113–121.

ClinicalTrials.gov (2022) ‘NCT05318469: Ivermectin in Combination With Balstilimab or Pembrolizumab in Metastatic Triple-Negative Breast Cancer’. Available at: https://clinicaltrials.gov